Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.

Published on Nov 13, 2019in PLOS ONE2.74
· DOI :10.1371/JOURNAL.PONE.0224027
Alessio Bruni (University of Modena and Reggio Emilia), Alessio Bruni15
Estimated H-index: 15
+ 23 AuthorsVieri Scotti19
Estimated H-index: 19
: Concurrent chemotherapy and radiotherapy (cCRT) is considered the standard treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Unfortunately, management is still heterogeneous across different specialists. A multidisciplinary approach is needed in this setting due to recent, promising results obtained by consolidative immunotherapy. The aim of this survey is to assess current LA-NSCLC management in Italy. From January to April 2018, a 15-question survey focusing on diagnostic/therapeutic LA-NSCLC management was sent to 1,478 e-mail addresses that belonged to pneumologists, thoracic surgeons, and radiation and medical oncologists. 421 answers were analyzed: 176 radiation oncologists, 86 medical oncologists, 92 pneumologists, 64 thoracic surgeons and 3 other specialists. More than a half of the respondents had been practicing for >10 years after completing residency training. Some discrepancies were observed in clinical LA-NSCLC management: the lack of a regularly planned multidisciplinary tumor board, the use of upfront surgery in multistation stage IIIA, and territorial diffusion of cCRT in unresectable LA-NSCLC. Our analysis demonstrated good compliance with international guidelines in the diagnostic workup of LA-NSCLC. We observed a relationship between high clinical experience and good clinical practice. A multidisciplinary approach is mandatory for managing LA-NSCLC.
📖 Papers frequently viewed together
8 Citations
131 Citations
#1Scott J. Antonia (Katholieke Universiteit Leuven)H-Index: 80
#2A. VillegasH-Index: 9
Last. Mustafa OzgurogluH-Index: 31
view all 33 authors...
Abstract Background An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non–small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for the second primary end point of overall survival. Methods We randomly assigned patients, in a 2:1 ratio, to receive durvalumab intravenously, at a dose of ...
1,045 CitationsSource
#1Thomas V. Bilfinger (SBU: Stony Brook University)H-Index: 41
#2Denise Albano (SBU: Stony Brook University)H-Index: 3
Last. Barbara Nemesure (SBU: Stony Brook University)H-Index: 41
view all 5 authors...
Abstract Background Evidence favoring a multidisciplinary team (MDT) approach in the treatment of lung cancer is scarce, especially in the United States. The purpose of the present investigation was to evaluate survival outcomes of lung cancer patients treated with an MDT compared with a traditional care model. Patients and Methods The Stony Brook Cancer Center Registry was used to identify all lung cancer cases diagnosed between 2002 and 2016. We compared survival outcomes among 1956 lung cance...
28 CitationsSource
#1S Michael Crawford (Airedale NHS Foundation Trust)H-Index: 6
In discussing the modest improvement in lung cancer survival from 1996 to 2013, Exarchakou and colleagues1 point to better provision of specialist thoracic surgical services as the reason for more patients undergoing surgery. These developments …
3 CitationsSource
BackgroundMost patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti–programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. MethodsWe randomly assigned patients, i...
1,633 CitationsSource
#1Markus Glatzer (Kantonsspital St. Gallen)H-Index: 9
#2Olgun ElicinH-Index: 10
Last. Paul Martin Putora (Kantonsspital St. Gallen)H-Index: 16
view all 5 authors...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsmall cell lung cancer (NSCLC). Treatment outcomes have improved over the last decades. Several treatment regimens have been shown effective and safe. This review summarises the results of significant studies between 1996 and 2015 on concomitant and sequential radiochemotherapy regimens and radiation dose per fraction. Beside therapy regimens, optimised radiotherapy planning is indispensable to impr...
15 CitationsSource
#1Wilfried EberhardtH-Index: 58
#2Christoph PöttgenH-Index: 23
Last. Martin StuschkeH-Index: 55
view all 22 authors...
Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2) disease and with selected IIIB disease. Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after induction. Patients and Methods Patients with pathologically proven IIIA(N2) and selected patient...
165 CitationsSource
#1Miklos Pless (Winterthur Museum, Garden and Library)H-Index: 33
#2Roger Stupp (UZH: University of Zurich)H-Index: 102
Last. Solange PetersH-Index: 65
view all 21 authors...
Summary Background One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate whether the addition of neoadjuvant radiotherapy improves outcomes. Methods We enrolled patients in 23 centres in Switzerland, Germany and Serbia. Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer and were randomly assigned to treatment groups in a 1:1 ratio. Those in the c...
177 CitationsSource
#1Belinda A. Campbell (University of Melbourne)H-Index: 16
#2David Ball (University of Melbourne)H-Index: 59
Last. Françoise Mornex (UCBL: Claude Bernard University Lyon 1)H-Index: 51
view all 3 authors...
Clinical guidelines widely recognize the importance of multidisciplinary meetings (MDM) in the optimal care of lung cancer patients. The published literature suggest that dedicated Lung Cancer MDM lead to increased treatment utilization rates and improved survival outcomes for patients with lung cancer. For radiation oncologists, Lung Cancer MDM have been proven to support evidence-based practice and improve the utilization of radiotherapy. Lung Cancer MDM also allow for education and promotion ...
14 CitationsSource
#1Jeffrey D. Bradley (WashU: Washington University in St. Louis)H-Index: 62
#2Rebecca Paulus (Radiation Therapy Oncology Group)H-Index: 35
Last. Hak Choy (UTSW: University of Texas Southwestern Medical Center)H-Index: 61
view all 22 authors...
Summary Background We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer. Methods In this open-label randomised, two-by-two factorial phase 3 study in 185 institutions in the USA and Canada, we enrolled patients (aged ≥18 years) with unresectable stage III non-small-cell lung cancer, a Zubrod performan...
1,084 CitationsSource
#1Paul De Leyn (Katholieke Universiteit Leuven)H-Index: 41
#2Christophe Dooms (Katholieke Universiteit Leuven)H-Index: 30
Last. Marcin ZielińskiH-Index: 26
view all 12 authors...
Accurate preoperative staging and restaging of mediastinal lymph nodes in patients with potentially resectable non-small-cell lung cancer (NSCLC) is of paramount importance. In 2007, the European Society of Thoracic Surgeons (ESTS) published an algorithm on preoperative mediastinal staging integrating imaging, endoscopic and surgical techniques. In 2009, the International Association for the Study of Lung Cancer (IASLC) introduced a new lymph node map. Some changes in this map have an important ...
369 CitationsSource
Cited By4
#1Vittorio Gebbia (University of Palermo)H-Index: 45
#2A. GuariniH-Index: 4
Last. Alberto Firenze (University of Palermo)H-Index: 16
view all 26 authors...
To date, the virtual multidisciplinary tumor boards (vMTBs) are increasingly used to achieve high-quality treatment recommendations across health-care regions, which expands and develops the local MTB team to a regional or national expert network. This review describes the process of lung cancer-specific MTBs and the transition process from face-to-face tumor boards to virtual ones. The review also focuses on the project organization's description, advantages, and disadvantages. Semi-structured ...
#1Anna MerlottiH-Index: 11
#2Alessio BruniH-Index: 15
Last. Stefano Arcangeli (University of Milan)H-Index: 24
view all 13 authors...
INTRODUCTION Almost 30% of non-small cell lung cancer (NSCLC) patients have locally advanced-stage disease. In this setting, definitive radiotherapy concurrent to chemotherapy plus adjuvant immunotherapy (cCRT + IO) is the standard of care, although only 40% of these patients are eligible for this approach. AIMS A comparison between cCRT and hypofractionated radiotherapy regimens (hypo-fx RT) with the addition of sequential chemotherapy (sCHT) could be useful for future combinations with immunot...
#1Marco Perna (UniFI: University of Florence)H-Index: 5
#2Vieri Scotti (UniFI: University of Florence)H-Index: 19
Last. Alessio BruniH-Index: 15
view all 26 authors...
ABSTRACT Introduction : In this observational, retrospective, multi-center study, we aim to assess the safety of the combination of local metastasis-directed radiotherapy (RT) and immunotherapy in a cohort of advanced NSCLC (aNSCLC) patients. Material and Methods : We collected clinical data of aNSCLC patients who received concomitant RT and anti-PD1/PD-L1 inhibitors in seven Italian centers from September 2015 to June 2019. Concomitant RT was defined as delivered ≤4 weeks before or after the fi...
#1Stefano PartelliH-Index: 43
#1S. Partelli (Esso)H-Index: 1
Last. Philip Poortmans (European CanCer Organisation)H-Index: 4
view all 23 authors...
Abstract ECCO Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give patients, health professionals, managers and policymakers a guide to essential care throughout the patient journey. Pancreatic cancer is an increasing cause of cancer mortality and has wide variation in treatment and care in Europe. It is a major healthcare burden and has complex diagnosis and treatment challenges. Care must be carr...
1 CitationsSource